0.6096

1.11% 0.0026

Moleculin Biotech Inc (MBRX)

Overview News Price History Financials Discussions Forecast Stock Split

Moleculin Biotech Inc stock is traded at $0.6096, with a volume of 746.72K. It is up +1.11% in the last 24 hours and down -70.52% over the past month. Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions. The Company operates in one reportable segment, which is the development and commercialization of drug products.

Previous Close:

$0.6122

Open:

$0.6382

24h Volume:

746.72K

Relative Volume:

0.66

Market Cap:

$4.33M

Revenue:

Net Income/Loss:

$-30.33M

P/E Ratio:

-0.0217

EPS:

-28.0369

Net Cash Flow:

$-24.28M

1W Performance:

+43.82%

1M Performance:

-70.52%

6M Performance:

-86.43%

1Y Performance:

-96.37%

1-Day Range:

$0.56

$0.665

1-Week Range:

$0.41

$0.665

52-Week Range:

$0.1614

$17.22

Moleculin Biotech Inc Stock (MBRX) Company Profile

Name

Moleculin Biotech Inc

Sector

Healthcare (1089)

Industry

Biotechnology (604)

Phone

713-300-5160

Address

5300 MEMORIAL DRIVE, HOUSTON, TX

Employee

Twitter

@moleculinbio

Next Earnings Date

2026-08-11

Latest SEC Filings

MBRX's Discussions on Twitter

Compare MBRX vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
MBRX Moleculin Biotech Inc	0.6096	4.35M	0	-30.33M	-24.28M	-28.04
VRTX Vertex Pharmaceuticals Inc	515.67	128.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	805.59	82.72B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	993.07	53.26B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	215.47	43.66B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	362.63	39.31B	5.76B	514.49M	1.10B	4.4813

Moleculin Biotech Inc Stock (MBRX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-09-25	Resumed	H.C. Wainwright	Buy
Feb-12-25	Downgrade	Maxim Group	Buy → Hold
Jul-18-22	Resumed	Oppenheimer	Outperform

Moleculin Biotech Inc Stock (MBRX) Latest News

Aug 15, 2026

Maxim Group Maintains Moleculin Biotech(MBRX.US) With Buy Rating, Cuts Target Price to $2 - Moomoo

Aug 15, 2026

Aug 14, 2026

Moleculin Biotech Releases Q2 2026 Financial Results - AlphaStreet

Aug 14, 2026

Moleculin Biotech (NASDAQ: MBRX) seeks reverse split and plan changes at 2026 meeting - Stock Titan

Aug 14, 2026

Why Did MBRX Stock Climb 14% Today? - Stocktwits

Aug 14, 2026

Moleculin Biotech 2Q Research and Development Expenses $5.5M >MBRX - Moomoo

Aug 14, 2026

Form 8K Moleculin Biotech Inc For: 14 August By Investing.com - Investing.com Canada

Aug 14, 2026

Moleculin Biotech Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of Pivotal MIRACLE Trial - The Manila Times

Aug 14, 2026

Moleculin Biotech reports Q2 2026 loss of $7.6M, cash $7.3M; MIRACLE trial interim efficacy positive - TradingView

Aug 14, 2026

Moleculin Biotech Reports Second Quarter 2026 Financial - GlobeNewswire

Aug 14, 2026

Aug 13, 2026

Moleculin Biotech Inc reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 13, 2026

Moleculin Biotech (NASDAQ: MBRX) advances AML trial but warns on cash - Stock Titan

Aug 13, 2026

Moleculin Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com

Aug 13, 2026

Aug 10, 2026

Moleculin Biotech (MBRX): CVI and Heights disclose 1.86M-share, 9.9% ownership - Stock Titan

Aug 10, 2026

Q1 2025 Moleculin Biotech Inc Earnings Call Transcript - GuruFocus

Aug 10, 2026